Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus

Pediatric Allergy and Immunology

Volumn 18, Issue 4, 2007, Pages 346-353

  Heshmat, Nahla M ^a,b   El Kerdany, Tahany H ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b 13 El Obour Buildings ^*  (Egypt)

Author keywords

Antiphospholipid syndrome; Lupus nephritis; Systemic lupus erythematosus; Systemic lupus erythematosus disease activity index; Vascular endothelial growth factor

Indexed keywords

CYCLOPHOSPHAMIDE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN;

ADOLESCENT; ANGIOGENESIS; ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; COLLAGEN DISEASE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; TREATMENT PLANNING; URINALYSIS; VASCULITIS;

ADOLESCENT; ANTIBODIES, ANTINUCLEAR; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; BLOOD CELL COUNT; BLOOD SEDIMENTATION; CHILD; COMPLEMENT C3; CREATININE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULITIS;

EID: 34250716422     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2006.00510.x     Document Type: Article

References (54)

1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983 : 219 : 983 5.
2. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989 : 86 : 7311 5.
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989 : 246 : 1306 9.
4. Senger DR, Connolly DT, Van De Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990 : 50 : 1774 8.
5. Plate KH, Warnke PC. Vascular endothelial growth factor. J Neurooncol 1997 : 35 : 365 72.
6. Josko J, Gwozdz B, Jedrzejowska-Syzpulka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000 : 6 : 1047 52.
7. DeVries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992 : 255 : 989 91.
8. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995 : 26 : 86 91.
9. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993 : 53 : 4727 35.
10. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993 : 143 : 1255 62.
11. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond) 1992 : 359 : 845 8.
12. Brown LF, Yeo K-T, Berse B, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992 : 176 : 1375 9.
13. Brown LF, Olbricht SM, Berse B, et al. Expression of vascular permeability factor in delayed hypersensitivity skin reactions. J Immunol 1995 : 154 : 2801 7.
14. Brown LF, Harrist TJ, Yeo K-T, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol 1995 : 104 : 744 9.
15. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor and its receptors in psoriasis. J Exp Med 1994 : 180 : 1141 6.
16. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995 : 146 : 1029 39.
17. Ferrara N. Vascular endothelial growth factor - the trigger for neovascularization in the eye. Lab Invest 1995 : 72 : 615 8.
18. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995 : 108 : 2369 79.
19. Brenchley PEC. VPF/VEGF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996 : 9 : 1 8.
20. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000 : 84 : 742 6.
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 : 1 : 27 31.
22. Talks KL, Harris AL. Current status of antiangiogenic factors. Br J Haematol 2000 : 109 : 477 89.
23. Kadono T, Kikuchi K, Kubo M, et al. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996 : 35 : 392 7.
24. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994 : 180 : 341 6.
25. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994 : 152 : 4149 56.
26. Harada M, Mitsuyama K, Yoshida H, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998 : 27 : 377 80.
27. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J dermatol 1998 : 139 : 1049 51.
28. Robak E, Wozniacka A, Sysa-Jedrzejowska A, Stepien H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002 : 11 : 348 55.
29. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 : 25 : 1271 7.
30. Bombardier C, Gladman D, Urowitz B, Caron D. Derivation of the SLEDAI, a disease activity index for lupus patients. Arthritis Rheum 1992 : 35 : 630 7.
31. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999 : 42 : 1309 11.
32. Bowers LD. Kinetic serum creatinine assay I. The role of various factors in determining specificity. Clin Chem 1980 : 26 : 551 4.
33. Tan EM, Chan KF, Sullivan K, Rubin RL. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 1988 : 47 : 121 41.
34. Johnson AM. A new international reference preparation for proteins in human serum. Arch Pathol Lab Med 1993 : 117 : 29 31.
35. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996 : 271 : 603 6.
36. Blau HM, Banfi A. The well-tempered vessel. Nature Med 2001 : 7 : 532 4.
37. Navarro C, Candia-Zuniga L, Silveira LH, et al. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus 2002 : 11 : 21 4.
38. Robak E, Sysa-Jedrzejewska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 2003 : 12 : 293 8.
39. Avihingsanon Y, Phumesin P, Benjachat T, et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006 : 69 : 747 53.
40. Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992 : 42 : 1457 61.
41. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996 : 7 : 661 6.
42. Honkanen EO, Teppo AM, Gronhagen-Riska C. Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis. Kidney Int 2000 : 57 : 2243 9.
43. Iruela-Arispe L, Gordon K, Hugo C, et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995 : 147 : 1715 27.
44. Noguchi K, Yoshikawa N, Ito-Kariya S, et al. Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998 : 9 : 1815 25.
45. Ostendorf T, Kunter U, Eitner F, et al. VEGF (165) mediates glomerular endothelial repair. J Clin Invest 1999 : 104 : 913 23.
46. Amengual O, Atsumi T, Khmashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998 : 79 : 279 81.
47. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome. Arthritis Rheum 1997 : 40 : 834 41.
48. Mechtcheriakova D, Wlachos AHH, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999 : 93 : 3811 23.
49. Colville-Nash PR, Scott DI. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992 : 51 : 919 25.
50. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994 : 180 : 341 6.
51. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994 : 152 : 4149 56.
52. Nagashima M, Yoshino S, Ishwata I, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995 : 22 : 1624 30.
53. Edworthy SM. Clinical manifestations of systemic lupus erythematosus. In : Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS, eds. Kelley's Textbook of Rheumatology, 6th edn. Philadelphia : WB Saunders 2001 : 1105 23.
54. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989 : 32 : 1107 18.